AZN.UK

10,356

+4.23%↑

GSK

1,381

+3.41%↑

HLN.UK

378.9

-0.84%↓

AZN.UK

10,356

+4.23%↑

GSK

1,381

+3.41%↑

HLN.UK

378.9

-0.84%↓

AZN.UK

10,356

+4.23%↑

GSK

1,381

+3.41%↑

HLN.UK

378.9

-0.84%↓

AZN.UK

10,356

+4.23%↑

GSK

1,381

+3.41%↑

HLN.UK

378.9

-0.84%↓

AZN.UK

10,356

+4.23%↑

GSK

1,381

+3.41%↑

HLN.UK

378.9

-0.84%↓

Search

Indivior PLC

Open

674 2.35

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

645.5

Max

674.5

Belangrijke statistieken

By Trading Economics

Inkomsten

63M

66M

Verkoop

-8M

299M

K/W

Sectorgemiddelde

347.5

59.668

EPS

0.319

Winstmarge

22.074

Werknemers

1,030

EBITDA

97M

106M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+57.99% upside

Dividenden

By Dow Jones

Volgende Winsten

24 apr 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-69M

867M

Vorige openingsprijs

671.65

Vorige sluitingsprijs

674

Indivior PLC Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

22 apr 2025, 22:00 UTC

Acquisities, Fusies, Overnames

Union Says Nippon Steel Can't Be Trusted With Buying U.S. Steel

22 apr 2025, 20:55 UTC

Winsten

Intuitive Surgical Reports Higher 1Q Profit, Warns of Tariff Hit to Margins

22 apr 2025, 23:49 UTC

Marktinformatie

Nikkei May Rise After Wall Street Rally -- Market Talk

22 apr 2025, 23:49 UTC

Marktinformatie

Gold Falls on Signs of Easing U.S.-China Tensions, Possible Profit-Taking -- Market Talk

22 apr 2025, 23:47 UTC

Top Nieuws

Trump Says He Has 'No Intention' of Firing Fed Chair Powell -- 4th Update

22 apr 2025, 23:08 UTC

Acquisities, Fusies, Overnames

Woodside: No Change to Annual Guidance

22 apr 2025, 23:07 UTC

Acquisities, Fusies, Overnames

Woodside: Assessing Impacts of Recent Tariff Announcements on Louisiana LNG

22 apr 2025, 23:07 UTC

Acquisities, Fusies, Overnames

Woodside: Advancing Talks Targeting Further Equity Selldown in Louisiana LNG

22 apr 2025, 23:06 UTC

Acquisities, Fusies, Overnames

Woodside: Trion Project 26% Complete, on Track for First Oil in 2028

22 apr 2025, 23:05 UTC

Acquisities, Fusies, Overnames

Woodside: Scarborough Energy Project on Track for First LNG Cargo in 2H 2026

22 apr 2025, 23:05 UTC

Acquisities, Fusies, Overnames

Woodside Energy: Scarborough Energy Project 82% Complete

22 apr 2025, 23:05 UTC

Acquisities, Fusies, Overnames

Woodside Energy: Beaumont New Ammonia Project on Track to Start in 2H

22 apr 2025, 23:05 UTC

Acquisities, Fusies, Overnames

Woodside Energy: Beaumont New Ammonia Project 90% Complete

22 apr 2025, 23:04 UTC

Acquisities, Fusies, Overnames

Woodside Energy: Share of Sangomar Production Maintained at 78 Million Bbl/Day in 1Q

22 apr 2025, 23:04 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Macquarie Set for A$500 Million Gain on Sale From Nomura Deal -- Market Talk

22 apr 2025, 23:04 UTC

Acquisities, Fusies, Overnames

Woodside Energy Sold 25.4% of Produced LNG at Prices Linked to Gas Hub Indices in 1Q

22 apr 2025, 23:03 UTC

Acquisities, Fusies, Overnames

Woodside Energy Cites Lower Output, Reduced Oil-Linked Prices for Revenue Fall

22 apr 2025, 23:03 UTC

Acquisities, Fusies, Overnames

Woodside Energy 1Q Revenue Down 5% on Prior Quarter

22 apr 2025, 23:03 UTC

Acquisities, Fusies, Overnames

Woodside Energy 1Q Revenue US$3.315 Billion

22 apr 2025, 23:02 UTC

Acquisities, Fusies, Overnames

Woodside Cites Weather Impacts at North West Shelf, Pluto Unplanned Outages in 1Q

22 apr 2025, 23:02 UTC

Acquisities, Fusies, Overnames

Woodside Energy 1Q Oil, Natural Gas Output Down 4% on Prior Quarter

22 apr 2025, 23:01 UTC

Acquisities, Fusies, Overnames

Woodside Energy 1Q Oil, Natural Gas Output 49.1 Million BOE

22 apr 2025, 22:31 UTC

Winsten

Tesla Profit Sinks, Hurt by Backlash Over Elon Musk's Political Role -- Update

22 apr 2025, 22:26 UTC

Top Nieuws

Trump Is Laying the Groundwork to Blame Powell for Any Downturn -- Update

22 apr 2025, 22:16 UTC

Top Nieuws

Trump Says He Has 'No Intention' of Firing Fed Chair Powell -- 3rd Update

22 apr 2025, 22:16 UTC

Marktinformatie

Turkey Remains on Course for Steadily Lower Inflation, Finance Minister Says -- Market Talk

22 apr 2025, 22:04 UTC

Top Nieuws

China Tariffs 'Won't Be Anywhere Near' 145%: Trump -- Barrons.com

22 apr 2025, 21:42 UTC

Winsten

Tesla Profit Sinks, Hurt by Backlash Over Elon Musk's Political Role -- WSJ

22 apr 2025, 21:21 UTC

Top Nieuws
Winsten

Tesla Profit Sinks, Hurt by Political Backlash -- 3rd Update

22 apr 2025, 21:19 UTC

Top Nieuws

Investors Hope for No Surprises as Boeing Reports Earnings -- Barrons.com

Peer Vergelijking

Prijswijziging

Indivior PLC Prognose

Koersdoel

By TipRanks

57.99% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 1,087.77Ā GBXĀ  57.99%

Hoogste 1,196.04Ā GBX

Laagste 971.782Ā GBX

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Indivior PLC - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Indivior PLC

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.